The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Abstract
Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with the severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.Methods We systematically searched PubMed, Scopus, and Web of Science from database inception to July 1, 2021, to identify eligible observational studies examining the risk of incident CVD events amongst adult (age ≥18 years) individuals with and without NAFLD and in which NAFLD was diagnosed by imaging, International Classification of Diseases codes, or liver biopsy. The primary outcomes were CVD death, non-fatal CVD events, or both. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on Open Science Framework, number osf.io/5z7gf.Findings We identified 36 longitudinal studies with aggregate data on 5 802 226 middle-aged individuals (mean age 53 years [SD 7]) and 99 668 incident cases of fatal and non-fatal CVD events over a median follow-up of 6·5 years (IQR 5·0-10·2). NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61; I 2=86·18%). This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72; I 2=73·84%). All risks were independent of age, sex, adiposity measures, diabetes, and other common cardiometabolic risk factors. Sensitivity analyses did not modify these results.Interpretation NAFLD is associated with an increased long-term risk of fatal or non-fatal CVD events. CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage. These results provide evidence that NAFLD might be an independent risk factor for CVD morbidity and mortality.Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40), 25”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although some studies indicated a higher risk of cardiovascular disease-related mortality (HR 1.30), 25,26 others did not con fi rm this result in the general population, but only in those with biopsy-proven MASH 24 or other risk factors like T2D. 15”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 80
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Self-citationNonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251
Cited by
Sorted by citations
Items 101–200 of 691
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications
Furuta, K., Tang, X., Islam, S., Tapia, A., Chen, Z. B., & Ibrahim, S. H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108372 · Cited by 36
Lonardo, A., & Ndrepepa, G. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.20 · Cited by 33
Ballestri, S., Mantovani, A., Girolamo, M. D., Baldelli, E., Capitelli, M., & Lonardo, A. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.23 · Cited by 33
Self-citationBoccatonda, A., Cane, L. D., Marola, L., D'Ardes, D., Lessiani, G., di Gregorio, N., Ferri, C., Cipollone, F., Serra, C., Santilli, F., et al. (2024) · Life · doi:10.3390/life14040473 · Cited by 35
Tampaki, M., Tsochatzis, E. A., Lekakis, V., & Cholongitas, Ε. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156101 · Cited by 33
Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
Doycheva, I., & Ehrmann, D. A. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.020 · Cited by 33
Liu, Z., Suo, C., Fan, H. X., Zhang, T., Li, J., & Chen, X. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155270 · Cited by 32
Sung, K., Yoo, T. K., Lee, M. Y., Byrne, C. D., Zheng, M., & Targher, G. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318661 · Cited by 31
Self-citationCai, Y., Fang, L., Chen, F., Zhong, P., Zheng, X., Xing, H., Fan, R., Yuan, L., Peng, W., & Li, X. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101052 · Cited by 31
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 35
Clinical outcomes of MAFLD versus NAFLD : A meta‐analysis of observational studies
Pennisi, G., Infantino, G., Celsa, C., Maria, G. D., Enea, M., Vaccaro, M., Cannella, R., Ciccioli, C., Mantia, C. L., Mantovani, A., et al. (2024) · Liver International · doi:10.1111/liv.16075 · Cited by 29
Self-citationLiver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease
Lonardo, A., Ballestri, S., Baffy, G., & Weiskirchen, R. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.42 · Cited by 29
Rinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 31
Liver fat as risk factor of hepatic and cardiometabolic diseases
Demir, M., Bornstein, S. R., Mantzoros, C. S., & Perakakis, N. (2023) · Obesity Reviews · doi:10.1111/obr.13612 · Cited by 31
Dalbeni, A., Lombardi, R., Henrique, M. K. C. L., Zoncapè, M., Pennisi, G., Petta, S., Tateishi, R., Keklikkıran, Ç., Colecchia, A., Sacerdoti, D., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000694 · Cited by 29
Self-citationMai, Z., Chen, Y., Mao, H., & Wang, L. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13569 · Cited by 30
Lee, H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., & Kim, S. U. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003274 · Cited by 28
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 30
Moreno‐Vedia, J., Rosales, R., Ozcariz, E., Llop, D., Lahuerta, M., Benavent, M., Rodríguez‐Calvo, R., Plana, N., Pedragosa, À., Masana, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.775677 · Cited by 29
Mantovani, A., Morieri, M. L., Palmisano, L., Masulli, M., Cossu, E., Baroni, M. G., Bonomo, K., Cimini, F. A., Cavallo, M. G., Buzzetti, R., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01945-x · Cited by 29
Self-citationKtenopoulos, N., Sagris, Μ., Gerogianni, M., Pamporis, K., Apostolos, A., Balampanis, K., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910595 · Cited by 27
Clayton‐Chubb, D., Roberts, S. K., Majeed, A., Woods, R. L., Tonkin, A., Nelson, M. R., Chan, A. T., Ryan, J. L., Tran, C., Hodge, A. D., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01435-2 · Cited by 27
Impact of NAFLD and Fibrosis on Adverse Cardiovascular Events in Patients With Hypertension
Huang, Y., Wan, T., Hong, Y., Wang, X., Jiang, X., Yang, Y., Gao, H., Ji, J., Wang, L., Yang, Y., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24252 · Cited by 26
Human Gut Microbiota in Cardiovascular Disease
Ronen, D., Rokach, Y., Abedat, S., Qadan, A., Daana, S., Amir, O., & Asleh, R. (2024) · Comprehensive physiology · doi:10.1002/cphy.c230012 · Cited by 28
Roderburg, C., Krieg, S., Krieg, A. H., Vaghiri, S., Mohr, R. U., Konrad, M., Luedde, M., Luedde, T., Kostev, K., & Loosen, S. H. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02250-z · Cited by 25
Vaz, K., Kemp, W. W., Majeed, A., Lubel, J. S., Magliano, D. J., Glenister, K., Bourke, L., Simmons, D. S., & Roberts, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10706-1 · Cited by 25
Jain, P., Jain, A., Deshmukh, R., Samal, P. K., Satapathy, T., & Ajazuddin, M. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102584 · Cited by 26
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
Nonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 26
Jamalinia, M., Zare, F., Noorizadeh, K., & Lankarani, K. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17869 · Cited by 25
Mantovani, A., Lando, M. G., Borella, N. D., Scoccia, E., Pecoraro, B., Gobbi, F. G., Bisoffi, Z., Valenti, L. V. C., Tilg, H., Byrne, C. D., et al. (2024) · Liver International · doi:10.1111/liv.15925 · Cited by 25
Self-citationZhang, Z., Zhang, W., Liu, Z., Ou, J., Sun, Y., Zhang, L., & Ji, G. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.019 · Cited by 24
Gastaldelli, A., & Newsome, P. N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf094 · Cited by 24
Goh, R. S. J., Koh, J., Intaran, M. A. U., Chin, Y. H., Kong, G., Chong, B., Chia, J., Chan, M. Y., Mehta, A., Muthiah, M. D., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041834 · Cited by 25
Brar, A. S., Khanna, T., Sohal, A., Hatwal, J., Sharma, V., Singh, C. M., Batta, A., Chandra, P., & Mohan, B. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i1.111954 · Cited by 25
Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure
Inciardi, R. M., Mantovani, A., & Targher, G. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00613-1 · Cited by 25
Self-citationLiver stiffness as a cornerstone in heart disease risk assessment
Boeckmans, J., Sandrin, L., Knackstedt, C., & Schattenberg, J. M. (2023) · Liver International · doi:10.1111/liv.15801 · Cited by 24
Byrne, C. D., & Targher, G. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.06 · Cited by 24
Self-citationStatin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD
Schreiner, A. D., Zhang, J., Petz, C. A., Moran, W. P., Koch, D. G., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2024-001404 · Cited by 23
Bae, J., Han, E., Lee, H. W., Park, C., Chung, C. H., Lee, D. H., Cho, E. H., Rhee, E., Yu, J. H., Park, J. H., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0541 · Cited by 23
Yu, Y., Yang, Y., Li, Q., Yuan, J., & Zha, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-96478-6 · Cited by 23
Moncho, F., Benlloch, S., & Górriz, J. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf260 · Cited by 25
Yu, S., Jiang, J., Li, Q., Liu, X., Wang, Z., Yang, L., & Ding, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.855008 · Cited by 23
Fatty liver disease, heart rate and cardiac remodelling: Evidence from the UK Biobank
Jamialahmadi, O., Tavaglione, F., Rawshani, A., Ljungman, C. E. A., & Romeo, S. (2023) · Liver International · doi:10.1111/liv.15556 · Cited by 23
Dote‐Montero, M., Merchán-Ramírez, E., Osés, M., Echarte, J., Clavero‐Jimeno, A., Alcántara, J. M. A., Camacho-Cardeñosa, A., Cupeiro, R., Rodríguez-Miranda, M. D. L. N., López-Vázquez, A., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.014 · Cited by 24
Xing, M., Ni, Y., Zhang, Y., Zhao, X., & Yu, X. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1246157 · Cited by 23
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 25
Wen, W., Cai, X., Zhu, Q., Hu, J., Hong, J., Zhang, X., & Li, N. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2410280 · Cited by 22
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 24
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 24
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 23
Fuior, E. V., Zvintzou, E., Filippatos, T. D., Giannatou, K., Mparnia, V., Simionescu, M., Gafencu, A. V., & Kypreos, K. E. (2023) · Biomedicines · doi:10.3390/biomedicines11102696 · Cited by 25
Review article: vascular effects of PPARs in the context of NASH
Guixé‐Muntet, S., Biquard, L., Szabó, G., Dufour, J., Tacke, F., Francque, S., Rautou, P., & Gracia‐Sancho, J. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17046 · Cited by 22
Fernández, J. G., Prieto‐Torres, L., Martín, M. A., & Martínez‐Domínguez, S. J. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251335824 · Cited by 21
Li, W., Wen, W., Xie, D., Qiu, M. R., Cai, X., Zheng, S., & Huang, Y. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221119626 · Cited by 21
Bril, F., Pearce, R. W., Collier, T. S., & McPhaul, M. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac565 · Cited by 21
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Chen, B. Y., Tang, W. H. W., Rodriguez, M., Corey, K. E., Sanyal, A. J., Kamath, P. S., Bozkurt, B., Virk, H. U. H., Pressman, G. S., Lazarus, J. V., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757712 · Cited by 22
Self-citationLu, C., Chen, Y., Zhang, Y., & Zhao, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s426102 · Cited by 21
Xu, M., Tan, J., Liu, X., Li, H., Ge, C., Zhang, Y., Luo, F., Wang, Z., Xue, X., Xiong, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42040-9 · Cited by 21
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
Bea, S., Jeong, H. E., Filion, K. B., Yu, O. H., Cho, Y. M., Lee, B. H., Chang, Y., Byrne, C. D., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.49856 · Cited by 22
Self-citationZheng, M., Wang, X., Yin, Y., Chen, S., Guo, C., Wu, S., & Yu, Y. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100064 · Cited by 21
Clinical management of major depressive disorder with comorbid obesity
Opel, N., Hanßen, R., Steinmann, L. A., Roempler, J., Köhler‐Forsberg, O., Hahn, M., Ferretti, F., Palmer, C., Penninx, B. W. J. H., Gold, S. M., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00193-2 · Cited by 20
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 22
Increased risk for microvascular outcomes in NAFLD—A nationwide, population‐based cohort study
Ebert, T., Widman, L., Stenvinkel, P., & Hagström, H. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13673 · Cited by 20
Liao, Y.-L., Zhu, G.-Y., & Chang, C. W. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1291438 · Cited by 20
Zhou, Z., Sun, L., Zhou, W., Gao, W., Yuan, X., Zhou, H., Ren, Y., Li, B., Wu, Y., & She, J. (2025) · Liver Research · doi:10.1016/j.livres.2025.02.001 · Cited by 19
Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD
Lei, L., Wang, B., Zhao, L., Li, J., Yan, X., Jiang, J., Wang, L., Ren, G., Li, Y., Cheng, X., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54152 · Cited by 19
Mantovani, A., Csermely, A., Taverna, A., Cappelli, D., Benfari, G., Bonapace, S., Byrne, C. D., & Targher, G. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101416 · Cited by 19
Self-citationLi, Q., Wu, J., Sun, X., Huang, X., Huang, W., Weng, C., & Cai, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1119005 · Cited by 20
Nabi, O., Lapidus, N., Boursier, J., de Lédinghen, V., Kab, S., Renuy, A., Zins, M., Serfaty, L., & Lacombe, K. (2023) · Liver International · doi:10.1111/liv.15674 · Cited by 19
Mertens, J., Weyler, J., Dirinck, E. L., Vonghia, L., Kwanten, W. J., Gaal, L. F. V., Winter, B. Y. D., Francque, S., & Block, C. E. M. D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02764-y · Cited by 20
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective
Miedel, M. T., Schurdak, M. E., Stern, A. M., Soto–Gutiérrez, A., Strobl, E. V., Behari, J., & Taylor, D. L. (2025) · Seminars in Liver Disease · doi:10.1055/a-2649-1560 · Cited by 20
Zeng, J., Gu, C., Wen, C., & Shen, C. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02750-z · Cited by 18
Wang, A., Li, Q., Sun, Z., Wang, Y., Fu, S., Zhang, D., & Ma, X. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14211 · Cited by 19
Metabolic-associated fatty liver disease and the risk of cardiovascular disease
Zhang, P., Dong, X., Zhang, W., Wang, S., Chen, C., Tang, J., You, Y., Hu, S., Zhang, S., Wang, C., et al. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102063 · Cited by 18
Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study
Yoo, T. K., Lee, M. Y., Kim, S. H., Zheng, M., Targher, G., Byrne, C. D., & Sung, K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.01.013 · Cited by 18
Self-citationHepatic Innervations and Nonalcoholic Fatty Liver Disease
Ádori, M., Bhat, S. H., Gramignoli, R., Valladolid‐Acebes, I., Bengtsson, T., Uhlén, M., & Ádori, C. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-57237 · Cited by 20
Cho, Y. K., Kim, M., Kim, Y., Jung, C. H., Lee, W. J., & Park, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1163052 · Cited by 19
Jamalinia, M., & Lonardo, A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.34 · Cited by 18
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02408-7 · Cited by 17
Cluster Analysis in Diabetes Research: A Systematic Review Enhanced by a Cross-Sectional Study
Taurbekova, B., Sarsenov, R., Yaqoob, M. M., Atageldiyeva, K. K., Semenova, Y. M., Fazli, S., Starodubov, A., Angalieva, A., & Sarría‐Santamera, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103588 · Cited by 18
Galatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 18
Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis
van den Hoek, A. M., Özsezen, S., Caspers, M. P. M., van Koppen, A., Hanemaaijer, R., & Verschuren, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158229 · Cited by 17
Choe, H. J., Lee, H., Lee, D., Kwak, S., & Koo, B. K. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13125 · Cited by 17
Ren, R., & Zheng, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.003 · Cited by 17
Lombardi, R., Mantovani, A., Cespiati, A., Francione, P., Maffi, G., Zanna, E. D., Maffeis, C., Colecchia, A., Passigato, N., Ferrarese, A., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.09.023 · Cited by 17
Self-citationSun, Q., Tang, L., Wang, M., Zhu, P., Li, Y., Ma, H., Huang, O., Hong, L. L., Li, G., Byrne, C. D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.864570 · Cited by 17
Self-citationIncremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification
Georgiopoulos, G. A., Athanasopoulos, S., Mavraganis, G., Konstantaki, C., Papaioannou, M., Delialis, D., Angelidakis, L., Sachse, M., Papoutsis, D., Cavlan, B., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae619 · Cited by 16
Huber, Y., Hofmann, L. J., Prochaska, J. H., Koeck, T., Chalabi, J., Pfeiffer, N., Beutel, M. E., Strauch, K., Lackner, K. J., Tuescher, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70053 · Cited by 16
Nonalcoholic fatty liver disease and diabetes
Bellini, M. I., Urciuoli, I., Gaudio, G. D., Polti, G., Iannetti, G., Gangitano, E., Lori, E., Lubrano, C., Cantisani, V., Sorrenti, S., et al. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.668 · Cited by 18
Corbin, K. D., Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Frederich, R. C., Liu, J., Pong, A., Lin, J., Cater, N. B., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14923 · Cited by 17
Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
Ren, Z., Wesselius, A., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.002 · Cited by 17
Wang, M., Zhao, Y., He, Y., Zhang, L., Liu, J., Zheng, S., & Bai, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.018 · Cited by 17
How non-alcoholic fatty liver disease and cirrhosis affect the heart
Møller, S., Wiese, S. S., Barløse, M., & Hove, J. D. (2023) · Hepatology International · doi:10.1007/s12072-023-10590-1 · Cited by 16
Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
Tan, S.-H., & Zhou, X. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100301 · Cited by 16
Garofolo, M., Lucchesi, D., GIAMBALVO, M., Aragona, M., Bertolotto, A., Campi, F., Bianchi, C., Francesconi, P., Marchetti, P., Prato, S. D., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02171-9 · Cited by 16
Shibata, N., Morita, Y., Ito, T., Kanzaki, Y., Watanabe, N., Yoshioka, N., Arao, Y., Yasuda, S., Koshiyama, Y., Toyoda, H., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.005 · Cited by 17
Kang, M. K., Song, J. E., Loomba, R. S., Park, S. Y., Tak, W. Y., Kweon, Y. O., Lee, Y. R., & Park, J. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-74287-7 · Cited by 16
Lankarani, K. B., Jamalinia, M., Zare, F., Heydari, S. T., Ardekani, A., & Lonardo, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03121-x · Cited by 16
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 17
Self-citation
Metadata
- Authors
- Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G.
- Affiliations
- University of Verona (IT)
- Harvard University (US)
- Southampton General Hospital (GB)
- Corresponding author
- Targher, Giovanni
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 6
- Issue
- 11
- Pages
- 903-913
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3201276384
- Cited by
- 674
- References
- 75
- Citations by year
- 2026: 160 · 2025: 151 · 2024: 141 · 2023: 122 · 2022: 95 · 2021: 4
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- National Institute for Health Research Southampton Biomedical Research Centre (IS-BRC-20004)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular mortality, cardiovascular events, liver fibrosis, disease severity, cardiometabolic risk factors, cardiovascular risk factors, middle-aged adults, NAFLD staging
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Severity of Illness Index, Models, Statistical, Survival Analysis, Observational Studies as Topic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
